Development of a supportive care framework for breast cancer survivor's unmet needs: A modified Delphi study
CONCLUSION: To address breast cancer survivors' unmet needs, a supportive framework was developed to actively enhance their health outcomes. However, further refinement and feasibility testing using mobile devices or artificial intelligence are required.IMPLICATIONS FOR THE PROFESSION AND PATIENT CARE: This pioneering framework prioritises addressing unmet needs and equips healthcare providers to assess and manage these needs effectively, facilitating the implementation of programs aimed at improving the well-being of breast cancer survivors.REPORTING METHOD: This study was guided by a modified guideline for the Conducting...
Source: Clinical Breast Cancer - February 15, 2024 Category: Cancer & Oncology Authors: Qian Dai Xiangyu Liu Xianghua Xu Yulu Fu Zhengdi She Yuansi Huang Yimin Xia Yongyi Chen Andy S K Cheng Michael Feuerstein Source Type: research

Doxorubicin Exposure and Breast Cancer Risk in Survivors of Adolescent and Adult Hodgkin Lymphoma
CONCLUSION: This study shows that treatment with doxorubicin is associated with increased BC risk in both adolescent and adult HL survivors. Our results have implications for BC surveillance guidelines for HL survivors and treatment strategies for patients with newly diagnosed HL.PMID:38359378 | DOI:10.1200/JCO.23.01386 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 15, 2024 Category: Cancer & Oncology Authors: Suzanne I M Neppelenbroek Yvonne M Geurts Berthe M P Aleman Pieternella J Lugtenburg Saskia E Rademakers Roel J de Weijer Maaike G A Schippers Bastiaan D P Ta Wouter J Plattel Jos ée M Zijlstra Richard W M van der Maazen Marten R Nijziel Francisca Ong Er Source Type: research

Elucidating Axillary Soft Tissue Involvement in Breast Cancer: Unveiling Metastatic Mechanisms and Therapeutic Perspectives
Clin Breast Cancer. 2024 Jan 29:S1526-8209(24)00024-7. doi: 10.1016/j.clbc.2024.01.013. Online ahead of print.ABSTRACTThis perspective focuses on axillary soft tissue (AXT) involvement in breast cancer, revealing diverse pathological entities beyond traditional axillary lymph node metastasis. AXT involvement is linked to increased risks of distant metastasis and locoregional failure, emphasizing its significance in predicting breast cancer outcomes. We posit that AXT involvement could signify a retrograde metastatic event stemming from reactivated circulating tumor cells navigating towards the axillary soft tissue guided b...
Source: Clinical Breast Cancer - February 15, 2024 Category: Cancer & Oncology Authors: Kefah Mokbel Source Type: research

Primary fallopian tube cancer followed by primary breast cancer in RAD51C mutation carrier treated with niraparib as first line maintenance therapy: a case report
We report the case of a 65-year-old woman diagnosed with stage IIIC high-grade serous primary fallopian tube cancer. The patient had no family history of breast or ovarian cancer. The patient received three cycles of neoadjuvant chemotherapy with paclitaxel and carboplatin and achieved a complete response. After interval debulking surgery, the patient received three cycles of adjuvant chemotherapy. Collection and extraction of saliva DNA for next-generation sequencing identified a RAD51C mutation c.838-2 A > G. The patient received niraparib as front-line maintenance treatment. After 36 months of niraparib treatment, th...
Source: Clinical Breast Cancer - February 15, 2024 Category: Cancer & Oncology Authors: Hua Yuan Rong Zhang Ning Li Hongwen Yao Source Type: research

The clinical impact of plasma estrogen receptor-1 mutation in patients with metastatic breast cancer: A meta-analysis
CONCLUSION: According to the findings of this meta-analysis, the assessment for plasma ESR1 mutations may provide prognostic and clinical guidance regarding subsequent endocrine therapy decisions for ER-positive, metastatic BC patients who had received prior therapy with AIs.PMID:38353504 | DOI:10.17219/acem/175816 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 14, 2024 Category: Cancer & Oncology Authors: Xiaoli Zhang Ye Tian Dan Mo Wenli Chen Yi Ding Yanjiang Yang Xinning Li Source Type: research

Developing questions to assess and measure patients' perceived survival benefit from adjuvant endocrine therapy in breast cancer: a mixed methods pilot study
Clin Exp Med. 2024 Feb 14;24(1):36. doi: 10.1007/s10238-023-01261-4.ABSTRACTThis mixed method study developed multiple question types to understand and measure women's perceived benefit from adjuvant endocrine therapy. We hypothesis that patients do not understand this benefit and sought to develop the questions needed to test this hypothesis and obtain initial patient estimates. From 8/2022 to 3/2023, qualitative interviews focused on assessing and modifying 9 initial varied question types asking about the overall survival (OS) benefit from adjuvant endocrine therapy. Subsequent focus groups modified and selected the opti...
Source: Clinical Breast Cancer - February 14, 2024 Category: Cancer & Oncology Authors: Bernard Tawfik Kendal Jacobson Ursa Brown-Glaberman Mikaela Kosich M Lee Van Horn Jacklyn Nemunaitis Zoneddy Dayao V Shane Pankratz Andrew L Sussman Dolores D Guest Source Type: research

Effectiveness and safety of primary prophylaxis with G-CSF for lung cancer: a systematic review and meta-analysis to develop clinical practice guidelines for the use of G-CSF 2022
CONCLUSION: Limited data are available on G-CSF prophylaxis in lung cancer. Primary prophylaxis with G-CSF may be weakly recommended in Japanese patients with NSCLC undergoing docetaxel and ramucirumab combination therapy.PMID:38353907 | DOI:10.1007/s10147-024-02469-4 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 14, 2024 Category: Cancer & Oncology Authors: Eiki Ichihara Nobuaki Ochi Go Makimoto Kenichiro Kudo Daijiro Harada Yukinori Ozaki Hiroshi Nishio Kenji Tsuchihashi Yuji Miura Makoto Endo Shingo Yano Dai Maruyama Tetsuhiro Yoshinami Nobuyuki Susumu Munetaka Takekuma Takashi Motohashi Mamoru Ito Eishi B Source Type: research

Clinical Internal Dosimetry and Biodistribution of 177Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast Carcinoma
CONCLUSIONS: The results of our study demonstrated expected and favorable biodistribution and dosimetry with 177Lu-DOTA-trastuzumab in HER2-positive breast carcinoma patients. We noticed the mean absorbed dose to the normal organs within the limits of maximum tolerable dose, and also tumor dose was higher than the normal liver dose. Therefore, we conclude that 177Lu-DOTA-trastuzumab radioimmunotherapy is feasible and a safe treatment option for treating HER2-positive breast carcinoma patients.PMID:38350067 | DOI:10.1097/RLU.0000000000005067 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 13, 2024 Category: Cancer & Oncology Authors: Yoga S Narwadkar Rahul V Parghane Sudeep Sahu Sangita Lad Kamal Deep Gaurav Wanage Tejal Suralkar Sharmila Banerjee Sudeep Gupta Sandip Basu Rajendra A Badwe Source Type: research

Long-term Follow-up and Safety of Patients after an Upfront Therapy with Letrozole for Early Breast Cancer in Routine Clinical Care - The PreFace Study
CONCLUSIONS: The risk profile of postmenopausal BC patients selected for a five-year upfront letrozole therapy showed a moderate recurrence and death risk. However, in subgroups with unfavorable risk factors, prognosis warrants an improvement, which might be achieved with novel targeted therapies.PMID:38344045 | PMC:PMC10853028 | DOI:10.1055/a-2238-3153 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 12, 2024 Category: Cancer & Oncology Authors: Carolin C Hack Nicolai Maass Bahriye Aktas Sherko K ümmel Christoph Thomssen Christopher Wolf Hans-Christian Kolberg Cosima Brucker Wolfgang Janni Peter Dall Andreas Schneeweiss Frederik Marme Matthias Ruebner Anna-Katharin Theuser Nadine M Hofmann Sybil Source Type: research

KIF2C/MCAK a prognostic biomarker and its oncogenic potential in malignant progression, and prognosis of cancer patients: a systematic review and meta-analysis as biomarker
Crit Rev Clin Lab Sci. 2024 Feb 12:1-31. doi: 10.1080/10408363.2024.2309933. Online ahead of print.ABSTRACTKIF2C/MCAK (KIF2C) is the most well-characterized member of the kinesin-13 family, which is critical in the regulation of microtubule (MT) dynamics during mitosis, as well as interphase. This systematic review briefly describes the important structural elements of KIF2C, its regulation by multiple molecular mechanisms, and its broad cellular functions. Furthermore, it systematically summarizes its oncogenic potential in malignant progression and performs a meta-analysis of its prognostic value in cancer patients. KIF2...
Source: Clinical Breast Cancer - February 12, 2024 Category: Cancer & Oncology Authors: Nina-Naomi Kreis Ha Hyung Moon Linda Wordeman Frank Louwen Christine Solbach Juping Yuan Andreas Ritter Source Type: research

NCAPH drives breast cancer progression and identifies a gene signature that predicts luminal a tumour recurrence
CONCLUSIONS: The GSLA10 signature outperformed the Oncotype DX signature in discerning tumours with unfavourable outcomes, previously categorised as luminal A by Prediction Analysis of Microarray 50 (PAM50) across three independent human cohorts. This new signature holds promise for identifying luminal A tumour patients with adverse prognosis, aiding in the development of personalised treatment strategies to significantly improve patient outcomes.PMID:38344872 | PMC:PMC10859882 | DOI:10.1002/ctm2.1554 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 12, 2024 Category: Cancer & Oncology Authors: Marina Mendiburu-Eli çabe Natalia Garc ía-Sancha Roberto Corchado-Cobos Ang élica Martínez-López Hang Chang Jian Hua Mao Adri án Blanco-Gómez Ana Garc ía-Casas Andr és Castellanos-Martín N élida Salvador Alejandro Jim énez-Navas Manuel Jes ús Source Type: research

The effectiveness of interventions to reduce cancer-related stigma: An integrative review
CONCLUSIONS: Multi-component and interactive interventions show promise to relieve cancer-related stigma. More methodologically robust studies should be conducted in different cultures to elucidate the most appropriate interventions for different populations to reduce cancer-related stigma.IMPLICATION FOR THE PROFESSION AND PATIENT CARE: These findings will facilitate healthcare workers to design and implement interventions to reduce cancer-related stigma, thus improving the quality of life for cancer patients.PATIENT AND PUBLIC CONTRIBUTION: No patient and public contribution.PMID:38345136 | DOI:10.1111/jocn.17014 (Source...
Source: Clinical Breast Cancer - February 12, 2024 Category: Cancer & Oncology Authors: Shuang Zheng Shengjie Liu Qingmo Yang Sally Chan Wenhe Huang Xiaoying Jiang Jiemin Zhu Source Type: research

Validation of the prognostic performance of Breast Cancer Index (BCI) in hormone receptor-positive (HR+) postmenopausal breast cancer patients in the TEAM trial
CONCLUSIONS: The TEAM trial represents the largest prognostic validation study for BCI to date and provides a more representative assessment of late DR risk to guide individualized treatment decision-making for HR+ early-stage breast cancer patients.PMID:38345755 | DOI:10.1158/1078-0432.CCR-23-2436 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 12, 2024 Category: Cancer & Oncology Authors: John M S Bartlett Keying Xu Jenna Wong Gregory Pond Yi Zhang Melanie Spears Ranelle Salunga Elizabeth Mallon Karen J Taylor Annette Hasenburg Christos Markopoulos Luc Dirix Cornelis J H van de Velde Daniel Rea Catherine A Schnabel Kai Treuner Jane Bayani Source Type: research

LFSPROShiny: An Interactive R/Shiny App for Prediction and Visualization of Cancer Risks in Families With Deleterious Germline < em > TP53 < /em > Mutations
CONCLUSION: Since December 2021, we have applied LFSPROShiny to over 100 families from counseling sessions at the MD Anderson Cancer Center. Our study suggests that software tools with easy-to-use interfaces are crucial for the dissemination of risk prediction models in clinical settings, hence serving as a guideline for future development of similar models.PMID:38346271 | DOI:10.1200/CCI.23.00167 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 12, 2024 Category: Cancer & Oncology Authors: Nam H Nguyen Elissa B Dodd-Eaton Gang Peng Jessica L Corredor Wenwei Jiao Jacynda Woodman-Ross Banu K Arun Wenyi Wang Source Type: research

Response to anti-HER2 neoadjuvant chemotherapy in HER2-positive invasive breast cancers with different HER2 FISH patterns
CONCLUSIONS: Patients with HER2/CEP17≥2.0 and HER2 copy numbers ≥4.0 and <6.0 do not benefit to the same extent from current anti-HER2 therapies as FISH-positive patients with other patterns.PMID:38346865 | DOI:10.1136/jcp-2023-209069 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - February 12, 2024 Category: Cancer & Oncology Authors: Hong Lv Qian-Ming Bai Ming Li Meng-Yuan Cai Shu-Ling Zhou Yin Liu Zhong-Hua Wang Ruo-Hong Shui Hong-Fen Lu Xiao-Li Xu Bao-Hua Yu Xiao-Yu Tu Rui Bi Yu-Fan Cheng Xiao-Yan Zhou Zhi-Min Shao Wen-Tao Yang Source Type: research